MiR-184 Mediated the Expression of ZNF865 in Exosome to Promote Procession in the PD Model

Liu, Chang; Wang, Yang; Li, Jing-wen; Zhu, Xiaoyan; Jiang, Hai-song; Zhao, Hong; Zhang, Li-ming

doi:10.1007/s12035-023-03773-2

Cited by 3 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The unique phospholipid bilayer structure and nanoscale particle size of exosomes allow exosomes to cross the BBB [ 6 ]. Brain-derived exosomes can be isolated in peripheral body fluids, such as plasma, serum, urine, and saliva [ 7 , 8 , 9 , 10 ]. Exosomes can efficiently cross the BBB, and, therefore, exosomes from peripheral body fluids can be used to detect central nervous system (CNS) diseases [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Exosomes in the Diagnosis of Neuropsychiatric Diseases: A Review

Wu,

Shang,

Guo

et al. 2024

Biology

View full text Add to dashboard Cite

Exosomes are 30–150 nm small extracellular vesicles (sEVs) which are highly stable and encapsulated by a phospholipid bilayer. Exosomes contain proteins, lipids, RNAs (mRNAs, microRNAs/miRNAs, long non-coding RNAs/lncRNAs), and DNA of their parent cell. In pathological conditions, the composition of exosomes is altered, making exosomes a potential source of biomarkers for disease diagnosis. Exosomes can cross the blood–brain barrier (BBB), which is an advantage for using exosomes in the diagnosis of central nervous system (CNS) diseases. Neuropsychiatric diseases belong to the CNS diseases, and many potential diagnostic markers have been identified for neuropsychiatric diseases. Here, we review the potential diagnostic markers of exosomes in neuropsychiatric diseases and discuss the potential application of exosomal biomarkers in the early and accurate diagnosis of these diseases. Additionally, we outline the limitations and future directions of exosomes in the diagnosis of neuropsychiatric diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Exosomes in the Diagnosis of Neuropsychiatric Diseases: A Review

Wu,

Shang,

Guo

et al. 2024

Biology

View full text Add to dashboard Cite

show abstract

Targeting the RUNX3–miR-186-3p–DAT–IGF1R axis as a therapeutic strategy in a Parkinson’s disease model

Huang,

Wan,

2024

J Transl Med

View full text Add to dashboard Cite

With the increasing age of the population worldwide, the incidence rate of Parkinson’s disease (PD) is increasing annually. Currently, the treatment strategy for PD only improves clinical symptoms. No effective treatment strategy can slow down the progression of the disease. In the present study, whole transcriptome sequencing was used to obtain the mRNA and miRNA expression profiles in a PD mouse model, which revealed the pathogenesis of PD. The transcription factor RUNX3 upregulated the miR-186-3p expression in the PD model. Furthermore, the high miR-186-3p expression in PD can be targeted to inhibit the DAT expression, resulting in a decrease in the dopamine content of dopaminergic neurons. Moreover, miR-186-3p can be targeted to inhibit the IGF1R expression and prevent the activation of the IGF1R – P-PI3K – P-AKT pathway, thus increasing the apoptosis of dopaminergic neurons by regulating the cytochrome c – Bax – cleaved caspase-3 pathway. Our research showed that the RUNX3 – miR-186-3p – DAT – IGF1R axis plays a key role in the pathogenesis of PD, and miR-186-3p is a potential target for the treatment of PD. Supplementary Information The online version contains supplementary material available at 10.1186/s12967-024-05535-7.

show abstract

Exosome Cargo in Neurodegenerative Diseases: Leveraging Their Intercellular Communication Capabilities for Biomarker Discovery and Therapeutic Delivery

Zhang,

Yang,

et al. 2024

Brain Sciences

View full text Add to dashboard Cite

The inexorable progression of neurodegenerative diseases (NDs), including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and multiple sclerosis, is closely related to irreversible brain decline. Accurately characterizing pathophysiological features and identifying reliable biomarkers for early diagnosis and optimized treatment are critical. Hindered by the blood–brain barrier (BBB), obtaining sensitive monitoring indicators for disease progression and achieving efficient drug delivery remain significant challenges. Exosomes, endogenous nanoscale vesicles that carry key bioactive substances, reflect the intracellular environment and play an important role in cell signaling. They have shown promise in traversing the BBB, serving dual roles as potential biomarkers for NDs and vehicles for targeted drug delivery. However, the specific mechanisms by which exosome influence NDs are not fully understood, necessitating further investigation into their attributes and functionalities in the context of NDs. This review explores how exosomes mediate multifaceted interactions, particularly in exacerbating pathogenic processes such as oxidative stress, neuronal dysfunction, and apoptosis integral to NDs. It provides a comprehensive analysis of the profound impact of exosomes under stress and disease states, assessing their prospective utility as biomarkers and drug delivery vectors, offering new perspectives for tackling these challenging diseases.

show abstract

MiR-184 Mediated the Expression of ZNF865 in Exosome to Promote Procession in the PD Model

Cited by 3 publications

References 48 publications

Exosomes in the Diagnosis of Neuropsychiatric Diseases: A Review

Exosomes in the Diagnosis of Neuropsychiatric Diseases: A Review

Targeting the RUNX3–miR-186-3p–DAT–IGF1R axis as a therapeutic strategy in a Parkinson’s disease model

Exosome Cargo in Neurodegenerative Diseases: Leveraging Their Intercellular Communication Capabilities for Biomarker Discovery and Therapeutic Delivery

Contact Info

Product

Resources

About